Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Suzhou Bowei Biotechnology
Suzhou, Jiangsu Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Suzhou Bowei Biotechnology is a private Chinese biotech company focused on developing biological therapeutics, notably monoclonal antibodies. Its lead asset, EA5, is a humanized monoclonal antibody targeting complement system proteins for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). As of May 2025, EA5 is in Phase 1 clinical trials evaluating safety, pharmacokinetics, and pharmacodynamics in adult PNH patients. No published clinical results are available yet.
- Therapeutic areas
- OncologyImmunologyNeurologyHematology
- Modalities
- Monoclonal antibodyBiological products
- Industry
- Biotech
Beyond the preview
Go deeper on Suzhou Bowei Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Bowei Biotechnology.